Lupus & antiphospholipid syndrome
Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study
Authors' conclusion
In lupus nephritis the use of SGLT2i was associated with decreases in proteinuria. Beneficial changes in eGFR, haemoglobin and hematocrit trajectories after SGLT2i initiation were observed, independent of the proteinuria response.
Study context
- Population
- Patients with lupus nephritis (LN) and residual proteinuria under maintenance treatment (median age 35 years; 85% female)
- Participants
- 53 patients
- Exposure
- After vs before SGLT2i initiation
- Outcome
- Proteinuria after SGLT2i initiation
Methodological detailsbefore-and-after, linear mixed models for repeated measurements
- Before-and-after
- Linear mixed models for repeated measurements
Main finding
As reported in the abstract
Reduction in proteinuria, full cohort
37.6%
95%CI −6.8% to −76.3%
Observational data: associations, not effects.
Further findings
ml/min/1.73 m²
| Outcome | After SGLT2i | Before SGLT2i | P value |
|---|---|---|---|
| Annualized eGFR slopeEffect on eGFR observed in responders and non-responders | −2.9 (95% CI −2.7 to-3.1) | −6.3 (95% CI −5.7 to-6.9) | P < 0.001 |
Proteinuria response (≥30% decrease)
- Responders
- 32 (60%)
- Non-responders
- 21 (40%)
Haemoglobin and hematocrit, median increase
- Haemoglobin increase, g/dl
- 0.78 (95%CI 0.76-0.81)
- Hematocrit increase
- 2.33% (95%CI 2.24-2.41)
Safety
- Adverse events
- 6 (12%)
- Events leading to ED evaluation or hospitalization
- 3 (6%)
Original publication
Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study. Rheumatology (Oxford). Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →